Barclays analyst Peter Lawson assigned a Buy rating to Arcus Biosciences (RCUS – Research Report) yesterday and set a price target of $35.00. The company’s shares closed yesterday at $15.30.
According to TipRanks, Lawson is a 4-star analyst with an average return of 6.1% and a 45.45% success rate. Lawson covers the Healthcare sector, focusing on stocks such as Exelixis, Arcus Biosciences, and Iovance Biotherapeutics.
Arcus Biosciences has an analyst consensus of Strong Buy, with a price target consensus of $43.00, representing a 181.05% upside. In a report released on January 22, Mizuho Securities also maintained a Buy rating on the stock with a $51.00 price target.
See today’s best-performing stocks on TipRanks >>
Based on Arcus Biosciences’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $32 million and a GAAP net loss of $71 million. In comparison, last year the company earned a revenue of $33 million and had a GAAP net loss of $65 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Arcus Biosciences (RCUS) Company Description:
Arcus Biosciences, Inc. engages in the development and commercialization of immunotherapies. The firm compete in the segments of the pharmaceutical, biotechnology and other related markets that develop immunotherapies for the treatment of cancer. The company was founded by Terry J. Rosen and Juan Carlos Jaen in 2015 and is headquartered in Hayward, CA.
Read More on RCUS:
